Recently, AmoyDx (Xiamen) Biotech Co., Ltd. announced that it has been granted a European invention patent. The patent covers a highly sensitive molecular diagnostic method developed in-house for detecting specific gene mutations, which is critical for its tumor companion diagnostic technologies. This European patent grant marks a significant milestone in AmoyDx’s international intellectual property strategy and underscores the global recognition of its innovative and leading-edge core technologies.As a leading Chinese company in precision oncology, AmoyDx has long focused on the research, development, and commercialization of companion diagnostics. These diagnostics enable physicians to select the most appropriate targeted therapies based on a patient’s genetic profile, thereby improving treatment outcomes and avoiding ineffective prescriptions. The newly granted European patent not only facilitates market expansion within the European Union but also lays a solid foundation for future collaborations with global pharmaceutical companies.In recent years, AmoyDx has significantly increased its R&D investment and filed numerous patent applications across China, the United States, Europe, and other regions. This European patent represents a key step in its globalization strategy and highlights the growing innovation capacity and competitiveness of Chinese biotech firms on the international stage.
近日，厦门艾德生物医药科技股份有限公司（简称“艾德生物”）宣布成功获得一项欧洲发明专利证书。该专利涉及其自主研发的肿瘤伴随诊断技术，具体涵盖用于检测特定基因突变的高灵敏度分子诊断方法。此项专利在欧洲的授权，标志着艾德生物在国际知识产权布局方面取得重要进展，也体现了其核心技术在全球范围内的创新性和领先性。艾德生物作为中国领先的肿瘤精准医疗企业，长期专注于伴随诊断产品的研发与产业化。伴随诊断技术可帮助医生根据患者的基因特征选择最合适的靶向药物，从而提升治疗效果并减少无效用药。此次获得欧洲专利，不仅有助于公司在欧盟市场拓展相关产品，也为未来与国际药企开展合作奠定坚实基础。近年来，艾德生物持续加大研发投入，已在中国、美国、欧洲等多个国家和地区申请了多项专利。此次欧洲发明专利的取得，是其全球化战略的重要一步，也彰显了中国生物科技企业在国际舞台上的创新能力与竞争力。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/2735.html